If you have non–Hodgkin lymphoma (NHL), you may have questions about your prognosis. has a better prognosis than diffuse large B–cell lymphoma (DLBCL).
Abstract. It is difficult to find figures for the expected rate of early mortality in diffuse large B–cell non–Hodgkin lymphoma (DLBCL) as many of the patients who are .
Your guide to survival for non–Hodgkin lymphoma.. For diffuse large B cell lymphoma, doctors group these factors together to make a prognostic index.
Rituximab has improved survival of diffuse large B–cell lymphoma (DLBCL). Four risk groups were identified that predicted 5-year survival rates of 73%, 51%,